Gibbons v. GlaxoSmithKline, LLC
Gibbons v. GlaxoSmithKline, LLC
Trial Court Opinion
nen nnn ne nn ne nee ee ee nN II NEE I I OD Case MDL No. 2924 Document 614 Filed 01/29/21 Page 1 of 2
UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION
IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION MDL No. 2924
(SEE ATTACHED SCHEDULE)
CONDITIONAL TRANSFER ORDER (CTO —52)
On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to
28 U.S.C. § 1407. See
437 F.Supp.3d 1368(J.P.M.L. 2020). Since that time, 290 additional action(s) have been transferred to the Southern District of Florida. With the consent of that court, all such actions have been assigned to the Honorable Robin L. Rosenberg. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Florida and assigned to Judge Rosenberg. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under
28 U.S.C. § 1407to the Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the consent of that court, assigned to the Honorable Robin L. Rosenberg. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.
Inasmuch as no objection is FOR THE PANEL: ieited. time, the GL □□ onreD srarea MUCTIDISTRIGT LITIGATION John W. Nichols Clerk of the Panel
DIST RS ee ere and ‘ = Southern District of Florida KAY s by___Maria □□□ Clerk Sea of Date _Jan 29, 2021.
IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION MDL No. 2924
SCHEDULE CTO−52 − TAG−ALONG ACTIONS
DIST DIV. C.A.NO. CASE CAPTION CALIFORNIA NORTHERN CAN 3 21−00442 Gibbons v. GlaxoSmithKline, LLC et al LOUISIANA EASTERN LAE 2 21−00087 Wheeler v. Sanofi−Aventis U. S. LLC et al
Reference
- Status
- Unknown